European, randomized, phase 3 study
of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder. Coghill D et al. Eur Neuropsychopharmacol. 2013.
Long-Term Safety and Efficacy of Lisdexamfetamine Dimesylate in Children and Adolescents with ADHD:
A Phase IV, 2-Year, Open-Label Study in Europe
Coghill DR, et al. CNS Drugs. 2017
Health-related quality of life and functional
outcomes from a randomized-withdrawal study of long-term lisdexamfetamine dimesylate treatment in children and adolescents with attention-deficit/hyperactivity disorder. Banaschewski T et al. CNS Drugs. 2014.
The World Federation of ADHD
International Consensus Statement: 208 Evidence-based conclusions about the disorder. Faraone SV et al. Neurosci Biobehav Rev. 2021.